目 景 关于浙江和仁科技股份有限公司 非经营性资金占用及其他关联资金往来情况的专项审核说明 中国杭州市钱江新城新业路 8号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa.cn | | 页 次 | | --- | --- | | 一、非经营性资金占用及其他关联资金往来情况的专项 | | | 审核说明 | 1-2 | | 二、非经营性资金占用及其他关联资金往来情况汇总表 | 3-4 | 中国杭州市钱江新城新业路 8号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcp ...

三、分红送配方案情况 10派0.25元(含税) 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 15687.15万股，累计占流通股比： 59.81%，较上期变化： 40.34万 股。 | 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 通策医疗（600763）股份有限公司 | 4992.03 | 19.03 | 不变 | | 杭州磐源投资有限公司 | 4026.08 | 15.35 | 不变 | | 厦门硅谷韶华一号投资合伙企业(有限合伙) | 2627.39 | 10.02 | 不变 | | 杭州磐鸿投资管理合伙企业(有限合伙) | 1424.08 | 5.43 | 不变 | | 武汉雷石瑞丰股权投资合伙企业(有限合伙) | 784.00 | 2.99 | 不变 | | 尤飞煌 | 562.41 | 2.14 | 不变 | | 马兆林 | 406.08 | 1.55 | 1.41 | | 陈菊英 | 295.27 | 1.13 | 38.06 | | 沈毅 | 290.61 | 1.11 | 1.12 | | ...

根据浙江和仁科技股份有限公司（以下简称"公司"）第四届董事会第十次 会议决议，公司定于 2025 年 5 月 14 日召开 2024 年度股东大会，现将有关事项 通知如下： 一、召开本次股东大会的基本情况 证券代码：300550 证券简称：和仁科技 公告编号：2025-016 浙江和仁科技股份有限公司 关于召开 2024 年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1、股东大会届次：2024 年度股东大会 2、股东大会召集人：公司董事会 3、会议召开的合法、合规性：公司第四届董事会第十次会议审议通过了《关 于召开 2024 年度股东大会的通知的议案》，本次股东大会的召开符合法律法规、 规范性文件和《公司章程》的规定。 4、股权登记日：2025 年 5 月 8 日（星期四） 5、会议召开日期、时间： （1）现场会议召开时间：2025年5月14日（星期三）15:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025年5月14日的交易时间，即9:15—9：25，9：30—11:30 和13:00—15:00； ...

第四届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 浙江和仁科技股份有限公司（以下简称"公司"）第四届监事会第九次会议 于 2025 年 4 月 22 日在公司会议室以现场表决的方式召开。 召开本次会议的通知已于 2025 年 4 月 11 日以电子邮件方式通知各位监事。 本次会议由监事会主席陆婷女士主持，会议应到监事 3 名，实际出席会议监事 3 名，此次会议达到法定人数，符合《公司法》和《公司章程》的规定。 二、监事会会议审议情况 证券代码：300550 证券简称：和仁科技 公告编号：2025-004 浙江和仁科技股份有限公司 经与会监事审议并在议案表决票上签字表决，作出如下决议： 1、审议通过《关于 2024 年度监事会工作报告的议案》 表决结果：3 票同意，0 票反对，0 票弃权 《2024 年度监事会工作报告》详见巨潮资讯网（http://www.cninfo.com.cn）。 本议案尚需提交公司 2024 年度股东大会审议。 2、审议通过《关于公司 2024 年度报告全文以及摘要的议案》 表决结果 ...

证券代码：300550 证券简称：和仁科技 公告编号：2025-003 浙江和仁科技股份有限公司 第四届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江和仁科技股份有限公司（以下简称"公司"）第四届董事会第十次会议 于 2025 年 4 月 22 日以现场表决方式召开。 召开本次会议的通知已于 2025 年 4 月 11 日以电子邮件形式送达各位董事。 本次董事会会议应参与表决董事 7 名，实际参与表决董事 7 名，会议主持人为董 事长赵晨晖先生，本次会议的召集、召开及表决程序符合《公司法》等法律、法 规、规范性文件以及《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事审议并在议案表决票上签字表决，作出如下决议： 1. 审议通过《关于 2024 年度董事会工作报告的议案》 表决结果： 7 票同意，0 票反对，0 票弃权 公司独立董事向董事会递交了《2024 年度独立董事述职报告》，将在公司 2024 年度股东大会上述职。 表决结果： 7 票同意，0 票反对，0 票弃权 3. 审议通过《关于 202 ...

二、利润分配预案的基本情况 经中汇会计师事务所（特殊普通合伙）审计，公司 2024 年度实现归属于上 市公司股东的净利润 39,296,818.30 元 ，合并报表 2024 年度末累计未分配利润 204,332,390.16 元；母公司 2024 年度实现净利润 29,221,319.50 元，根据《公 司章程》规定，按照 2024 年度母公司实现净利润的 10%提取法定盈余公积金 2,922,131.95 元，母公司报表 2024 年度末累计未分配利润 210,984,682.52 元。 出于对投资者持续的回报以及公司长远发展考虑，公司拟定 2024 年度的利 润分配预案为：以未来实施 2024 年年度权益分配方案时股权登记日享有利润分 配、公积金转增股本权利的总股本为基数，向全体股东每 10 股派发现金红利 0.25 元（含税）、不送红股，不以资本公积转增股本。若利润分配方案实施完毕前， 公司股本发生变动，公司将维持每股分配比例不变，相应调整分配总额。 证券代码：300550 证券简称：和仁科技 公告编号：2025-007 浙江和仁科技股份有限公司 2024 年度利润分配预案的公告 本公司及董事会全体成 ...

Financial Performance - The company's revenue for Q1 2025 was ¥78,396,137.81, a decrease of 13.99% compared to ¥91,148,429.82 in the same period last year[5] - The net loss attributable to shareholders was ¥3,844,103.00, representing a significant increase of 645.00% from a loss of ¥515,984.62 in the previous year[5] - The company's basic and diluted earnings per share were both -¥0.0146, a decline of 630.00% from -¥0.0020 in the same period last year[5] - Net profit decreased to -¥4,119,299.87 from -¥341,004.41, indicating a significant increase in losses[18] - The total comprehensive income attributable to the parent company was -3,844,103.00, compared to -515,984.62 in the previous period, indicating a significant decline[19] Cash Flow - The net cash flow from operating activities improved by 26.22%, amounting to -¥33,386,117.18 compared to -¥45,250,595.69 in the prior year[5] - Cash inflows from operating activities totaled 64,104,234.14, up from 54,856,404.74 in the previous period[20] - Cash outflows from operating activities decreased to 97,490,351.32 from 100,107,000.43 in the previous period[20] - The net cash flow from investing activities was -16,927,357.81, a decline from 22,495,166.08 in the previous period[20] - Cash inflows from investing activities amounted to 49,492,068.74, compared to 30,003,489.00 in the previous period[20] - Cash outflows from investing activities increased to 66,419,426.55 from 7,508,322.92 in the previous period[20] - The net cash flow from financing activities was -31,137,333.73, worsening from -1,102,776.15 in the previous period[20] - The ending cash and cash equivalents balance was 456,877,114.76, down from 527,265,218.62 in the previous period[20] Assets and Liabilities - Total assets decreased by 2.86% to ¥1,420,322,605.37 from ¥1,462,115,708.52 at the end of the previous year[5] - The company's cash and cash equivalents decreased from ¥542,170,950.15 to ¥460,608,942.25, a decline of approximately 15.0%[14] - Accounts receivable decreased from ¥302,045,937.69 to ¥264,293,020.34, representing a reduction of about 12.5%[14] - Inventory increased from ¥15,837,019.24 to ¥22,897,125.06, showing a growth of approximately 44.3%[14] - Total current assets decreased from ¥1,201,113,121.11 to ¥1,162,590,297.32, a decline of about 3.2%[14] - Total liabilities decreased to ¥304,745,991.69 from ¥342,419,794.97, a reduction of approximately 11%[16] - The company’s total equity attributable to shareholders decreased by 0.35% to ¥1,106,846,526.61 from ¥1,110,690,629.61 at the end of the previous year[5] - The company’s equity attributable to shareholders decreased to ¥1,106,846,526.61 from ¥1,110,690,629.61, a decline of about 0.4%[16] Income and Expenses - Total operating revenue decreased to ¥78,396,137.81 from ¥91,148,429.82, representing a decline of approximately 14.5% year-over-year[17] - Total operating costs decreased to ¥83,707,202.02 from ¥90,767,716.86, a reduction of about 7.4% year-over-year[17] - Research and development expenses increased to ¥15,020,854.32 from ¥11,641,036.77, reflecting a growth of approximately 28.5% year-over-year[17] - The company reported a significant increase of 3477.31% in non-operating income, reaching ¥144,881.00, primarily from asset disposals[9] - The company reported a significant increase in credit impairment losses to ¥2,331,462.86 from a gain of ¥1,480,954.67[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,539, with the top ten shareholders holding a combined 34.34% of the shares[10] - The company reported a total of 243,780 shares under lock-up for executives, with no shares released during the current period[12] Other Financial Metrics - The company's financial expenses decreased by 86.28% to -¥247,884.29, primarily due to reduced interest income[9] - Other income increased by 146.27% to ¥3,121,440.23, mainly attributed to increased software product tax refunds[9] - The company has a significant amount of contract assets totaling ¥370,214,519.63, up from ¥302,818,803.26, indicating an increase of approximately 22.3%[14] - The company’s long-term receivables slightly decreased from ¥8,589,042.33 to ¥8,527,972.28, a decrease of about 0.7%[14] - The company’s trading financial assets increased from ¥20,025,416.66 to ¥30,243,166.66, reflecting a growth of approximately 50.9%[14] - The company’s total non-current assets include long-term equity investments of ¥5,002,753.38, unchanged from the previous period[14] - The company’s total liabilities and equity structure remains stable, with no significant changes reported in the current period[13]

Financial Performance - Heren Technology reported a revenue of RMB 500 million for the fiscal year 2023, representing a year-over-year growth of 15%[20]. - The company achieved a net profit of RMB 80 million, which is an increase of 10% compared to the previous year[20]. - The company's operating revenue for 2024 was ¥406,010,685.79, a decrease of 7.57% compared to ¥439,252,256.21 in 2023[25]. - The net profit attributable to shareholders for 2024 was ¥39,296,818.30, showing a slight increase of 0.46% from ¥39,116,183.90 in 2023[25]. - The net cash flow from operating activities significantly dropped by 90.41% to ¥7,996,955.78 in 2024 from ¥83,375,495.06 in 2023[25]. - The total assets at the end of 2024 increased by 1.65% to ¥1,462,115,708.52 compared to ¥1,438,378,630.67 at the end of 2023[25]. - The net assets attributable to shareholders rose by 2.91% to ¥1,110,690,629.61 at the end of 2024 from ¥1,079,270,615.54 at the end of 2023[25]. - The company reported a basic earnings per share of ¥0.15 for both 2024 and 2023, indicating no change[25]. - The weighted average return on equity for 2024 was 3.59%, a slight decrease from 3.69% in 2023[25]. - Heren Technology's gross margin improved to 45%, up from 42% in the previous year, reflecting better cost management[20]. Dividend Distribution - The company plans to distribute a cash dividend of 0.25 RMB per 10 shares to all shareholders, based on a total of 262,560,141 shares[12]. - For the 2024 profit distribution plan, the company will distribute a cash dividend of 0.25 yuan per 10 shares, totaling approximately 6,564,003.53 yuan based on a share base of 262,560,141 shares[188]. - The cash dividend represents 100% of the total profit distribution amount, indicating a strong commitment to returning value to shareholders[189]. Market Strategy and Expansion - Heren Technology plans to expand its market presence in Southeast Asia, targeting a 25% market share by 2025[20]. - The company aims to adapt to changes in national policies and macroeconomic conditions by continuing product and technology innovation and strengthening its market position[12]. - The company is actively working to establish a stable customer base by improving service quality and expanding its client resources[7]. - The company is focusing on the development of urban-level smart healthcare solutions, driven by policies such as the integration of medical services, insurance, and pharmaceuticals, which are expected to enhance the market for digital health cities[120][124]. Research and Development - The company is investing RMB 50 million in R&D for new digital health solutions, aiming to launch two new products by Q3 2024[20]. - The number of R&D personnel increased to 257 in 2024 from 247 in 2023, representing a growth of 4.05%[84]. - R&D investment amounted to ¥53,327,497.12 in 2024, accounting for 13.13% of operating revenue, compared to 12.79% in 2023[84]. - The company is developing a SaaS-based clinical information system aimed at improving hospital efficiency, ensuring data security, and enhancing patient care[81]. - A comprehensive SaaS lifecycle management system is in progress to connect patients, healthcare providers, and pharmacies, aiming to reduce costs and improve service quality[82]. Risk Management - The company faces risks related to major project implementation, which could significantly impact current operating performance if any major projects encounter issues[6]. - The company has a high customer concentration, primarily serving large and medium-sized medical institutions, which poses a risk if any major clients decide to terminate their cooperation[7]. - The company recognizes the risk of technology and talent loss in the software industry and is focused on retaining its core technical team through competitive compensation and training[10]. - The company aims to mitigate the risk of major client attrition by improving service quality and maintaining a market-oriented approach to stabilize its customer base[142]. Governance and Internal Control - The company has established a governance structure that ensures the protection of shareholder rights and compliance with relevant laws and regulations[199]. - The internal control system is continuously improved to enhance the company's operational standards[199]. - The company has implemented various measures to protect employee rights and ensure their health and safety[200]. - The company has established an independent financial department with a complete financial accounting system, adhering to the "Enterprise Accounting Standards" and ensuring independent financial decision-making[155]. Operational Challenges - The company is experiencing increased complexity in management control due to the expansion of its service offerings, which may affect its gross profit margin[9]. - The company is facing increased risks in project investment returns due to economic conditions and service fee collection models[113]. - The company has successfully won multiple large-scale projects, each exceeding 10 million yuan, including the Zhejiang Provincial People's Hospital and Gansu Southern Regional Medical Center projects[48]. Employee Management - The total number of employees at the end of the reporting period is 684, with 672 from the parent company and 12 from major subsidiaries[180]. - The total employee compensation for the year is 127.95 million yuan, accounting for 38.19% of the company's total costs[182]. - The company has a training plan aimed at enhancing employee skills and supporting sustainable development[183]. - Continuous investment in human resources is a core strategy, with a focus on effective planning and optimization of personnel allocation[140].

证券代码：300550 证券简称：和仁科技 公告编号：2025-002 浙江和仁科技股份有限公司 关于已披露日常经营合同收到中标通知书 的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江和仁科技股份有限公司（以下简称"和仁科技"或"公司"）于 2025 年 4 月 7 日披露了《关于日常经营合同预中标的提示性公告》（详见巨潮资讯网 http://www.cninfo.com.cn，公告编号：2025-001），公司近日收到新疆维吾尔 自治区政务服务和公共资源交易中心发出的《中标（成交）通知书》，和仁科技 被确定为"新疆维吾尔自治区中医医院智慧医院信息化建设项目"的中标人。 一、中标项目情况 浙江和仁科技股份有限公司董事会 2025 年 4 月 10 日 1、项目名称：新疆维吾尔自治区中医医院智慧医院信息化建设项目 2、采购人：新疆维吾尔自治区中医医院 3、采购代理机构：新疆维吾尔自治区政务服务和公共资源交易中心 4、项目中标金额报价：148,160,000 元。实际金额依据双方后续签订的合 同为准。 二、中标对公司的影响 若公司能顺利签订合同并且 ...

证券时报网讯，企查查APP显示，近日，浙江和众仁信科技有限公司成立，法定代表人为赵晨晖，注册 资本1亿元，经营范围包含：互联网数据服务；信息系统集成服务；数据处理服务；物联网技术服务； 物联网技术研发等。 企查查股权穿透显示，该公司由和仁科技等共同持股。 ...